HWPC withdraws the registration application for Arolol hydrochloride tablets
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, HWPC announced that the company recently received the "Notice of Termination of Drug Registration Application" approved and issued by the National Medical Products Administration, agreeing to the company's withdrawal of the registration application for Arolol Hydrochloride Tablets. Arolol Hydrochloride Tablets are mainly used for the treatment of primary hypertension (mild to moderate), angina pectoris, tachyarrhythmia, and essential tremor
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments